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Accepted 8 September 2014Allogeneic hematopoietic stem-cell transplantation (SCT)
is a potentially curative therapy for patients with a variety of
malignant and nonmalignant hematological disorders. Over
the last decades, substantial improvement has been achieved
in SCT outcomes [1]. A larger proportion of SCT recipients are
now long-term survivors and more attention is given to is-
sues of quality of life and late complications. Second malig-
nancies are a rare but well-deﬁned late complication after
allogeneic SCT with myeloablative conditioning (MAC), ac-
counting for 5% to 10% of late deaths [2-6]. The incidence is
gradually increasing after SCT, with no apparent plateau. The
Center for International Blood and Marrow Transplant
Research and the Fred Hutchinson Cancer Research Center
conducted the largest analysis to date of second malig-
nancies among 28,874 SCT recipients [2]. Second malig-
nancies were observed in 189 patients, with a cumulative
incidence of 1.0% at 10 years, 2.2% at 15 years, and 3.3% at 20
years. This rate was 2.1 higher than expected in a matched
general population. The majority of patients in this analysis
were given total body irradiation (TBI) during conditioning.
Signiﬁcantly elevated risks were observed for tumors of the
oral cavity, liver, central nervous system, thyroid, bone, soft
tissues, and melanoma of the skin. In a follow-up report,
Majhail et al. studied 4318 patients with acute myelogenous
leukemia (AML) and chronic myelogenous leukemia who
were given allogeneic SCT with chemotherapy-based MAC
consisting of busulfan and cyclophosphamide [3]. Sixty-six
patients had a second malignancy, with a 10-yearcumulative incidence of 1.2% in AML and 2.4% in chronic
myelogenous leukemia,1.4 times higher than expected in the
general population. Signiﬁcantly elevated risks were
observed for tumors of the oral cavity, esophagus, lung, soft
tissue, and brain. More recently, Atsuta et al. reported on 269
second malignancies among 17,545 Japanese SCT recipients,
with a cumulative incidence 1.7% at 10 years, which was 1.8
more than a matched general population [6]. Risks were
higher for oral cavity, esophageal, colon, skin, and brain
cancers. Thus, despite regional and genetic differences in
cancer incidence and sites, the impact of SCT on second
cancer was similar in the various studies. Collectively, TBI
was recognized as a major risk factor for nonsquamous cell
cancers, especially when administered at younger age (<30
years) [2]. Chronic GVHD was a risk factor for squamous cell
cancers, especially of the oral cavity. Advanced agewas also a
major risk factor for the occurrence of second malignancies.
The pathogenesis of second malignancies after allogeneic
SCT is multifactorial. Radiation and chemotherapy exposure
can induce breaks in the DNA double strand, resulting in
gene mutations, deletions, translocations, and genomic
instability conferred by loss of DNA repair [7]. Genomic al-
terations in mucosal epithelium, as evidenced by microsat-
ellite instability, are common, including in tissues affected by
graft-versus-host disease (GVHD), and may contribute to
second malignancies [8]. Oncogenic viruses in the context of
prolonged immune suppression may also take part in the
pathogenesis.
Reduced-intensity conditioning (RIC) has been widely
introduced over the last 15 years to allow SCT in older or
medically inﬁrm patients who are not eligible for standard
MAC. RIC has been able to markedly expand the eligible
population and the indications for SCT by reducing the
incidence of early transplantation-related complications.
One can intuitively expect that RIC will also reduce the
incidence of second malignancies [6]. However, older pa-
tients, who have often had more prior chemotherapy,
including a prior autologous SCT, are included in RIC studies.
High-dose TBI is not used; however, low-dose TBI or
chemotherapy may be even more carcinogenic as they may
leave damaged cells viable. Fludarabine, which is a major
component of RIC, has been associated with second
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especially when given with alkylating agents [9]. Most
importantly, chronic GVHD with the associated prolonged
immune suppression, a major risk factor for second malig-
nancies, may not be reduced by RIC. A large comparison of
RIC and MAC for AML, reported by the Center for Interna-
tional Blood and Marrow Transplant Research, has shown
that the late nonrelapse mortality negates any early decrease
in toxicity by RIC, resulting in similar survival. In particular,
chronic GVHD and late infections were not reduced with RIC
[10]. One could, therefore, also expect similar trends in the
incidence of second malignancies. However, due to the
relatively limited long-term follow-up so far of RIC re-
cipients, the incidence and risk factors for second malig-
nancies after RIC have not been deﬁned.
In a single-center analysis, we reported the incidence of
second malignancies in 931 patients given MAC (n ¼ 257),
RIC (n ¼ 449), or ﬂudarabine-based reduced-toxicity mye-
loablative conditioning (RTC, n ¼ 225) [5]. Twenty-seven
patients had a second malignancy, diagnosed a median of
43 months after SCT. The 10-year cumulative incidence was
5.6%, twice the expected rate in a matched normal popula-
tion. The incidence was 1.7%, 7.4%, and 5.7% after MAC, RIC,
and RTC, respectively (P ¼ .02). Multivariate analysis identi-
ﬁed ﬂudarabine-based conditioning (hazard ratio [HR], 3.5;
P ¼ .05), moderate-severe chronic GVHD (HR, 2.8; P ¼ .01),
and diagnosis of chronic myeloproliferative or nonmalignant
disease (HR, .2; P¼ .04) as risk factors for secondmalignancy.
These results suggested that the risk of second malignancies
is not reduced and is even possibly increased in the era of
ﬂudarabine-based RIC/RTC.
In this issue of Biology of Blood and Marrow Trans-
plantation, Ringden et al. explored the risk of second malig-
nancies in the largest cohort of RIC recipients reported so far,
consisting of 4269 patients with leukemia/myelodysplastic
syndrome or lymphoma [11]. The 10-year cumulative inci-
dence of all cancers was 3.35%. This risk was not higher than
expected in a general matched population. However, there
was an increased risk for cancers of the oral cavity/
oropharynx, bone, soft tissues, and melanoma. Advanced age
was the only independent predicting factor (HR, 3.1 for age>
50 years). Among patients ages 40 to 60 years old, there was
no difference in the incidence of second malignancies be-
tween RIC and MAC in leukemia/myelodysplastic syndrome
patients and there was a trend for lower incidence after RIC
in lymphoma patients.
These observations suggest that second malignancies
remain a risk after RIC, at least in certain sites. The riskincreases with follow-up, similar to the MAC setting with no
apparent plateau and probably with the same kinetics. The
involved sites are also similar after RIC and MAC. RIC reduces
the acute toxicity of SCT but not the incidence and severity of
chronic GVHD and other late effects that are related to
transplantation immunobiology. The comparison of the
incidence of second malignancies after RIC and MAC remains
inconclusive, as second cancers may become apparent more
than 10 years after SCT and a longer follow-up of a larger
cohort may be required. Patients and physicians should be
aware of this association and life-long cancer screening is
required for all transplantation survivors.ACKNOWLEDGMENTS
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